The program will feature a Keynote Lecture, Nobel Laureate Lecture, Plenary Lectures, Closing Lecture, Symposia, Roundtable Discussion, Platform and Poster Presentations.

**Scientific Program**

Keynote Lecture:

  • From Environmental Exposures to Disease Manifestation: The Lasting Impact of Arsenic: Professor Dr. Her Royal Highness Princess Chulabhorn Mahidol (President, Chulabhorn Research Institute)

Plenary Lectures:

  • One Health Innovations: Predicting and Preempting Spillover Infections: Julie L. Gerberding (Foundation for the National Institutes of Health, U.S.A.)
  • AMR in 2024: We Still Have an Awareness Problem: Helen W. Boucher (Tufts University School of Medicine, U.S.A.)
  • Drug Development and Regulatory Sciences: Turning Crises into Opportunities — A Valuable Perspective: Ram Sasisekharan (Massachusetts Institute of Technology, U.S.A.)
  • Two Sides of Precision Medicine: Proteomic Enablement of Biomarkers and Therapeutics: Jennifer van Eyk (Cedars-Sinai, Smidt Heart Institute, U.S.A.)
  • Programmable Therapeutics for Genetic Diseases: John M. Essigmann (Massachusetts Institute of Technology, U.S.A.)
  • The Lessons Learned from COVID-19: George F. Gao (Chinese Academy of Sciences, P.R. China)

Session Topics:

  1. AMR and One Health: Critical Issues
    • AMR Governance: Critical Challenges Beyond the Science: Adam Kamradt-Scott (Tufts University, U.S.A.)
    • AMR Clinical Trials in Asia – ADVANCE-ID: David Paterson (National University of Singapore, Republic of Singapore)
    • AMR (TBD): Ramanan Laxminarayan (University of Washington, U.S.A.)
  2. One Health and Climate Change
    • One Health and Climate Change: Maria Neira (WHO, Switzerland)
    • Climate Change and Emerging Infectious Diseases: Paul Hunter (University of East Anglia, U.K.)
    • Rational Design of Vaccines against Zika and Dengue Viruses: Lianpan Dai (Chinese Academy of Sciences, P.R. China)
    • Elimination of Hepatitis in Thailand by the Year 2030: Yong Poovorawan (Faculty of Medicine, Chulalongkorn University, Thailand)
  3. Role of Chemical and Biological Sciences for Discovery of Modern Drugs I
    • Phytochemicals of Liverworts: Structurers, Biological Activity, and Their Application to Foods and Medicinal Drugs: Yoshinori Asakawa (Tokushima Bunri University, Japan)
    • Phenotypic Assays and Analog Synthesis: Effective Tools for the Discovery and Development of Marine Natural Product Drug Leads: Raymond Andersen (University of British Columbia, Canada)
    • Discovery of Antiviral Natural Products Based on Native Mass Spectrometry and Molecular Networking: Yang Ye (Chinese Academy of Sciences, P.R. China)
    • Natural Product Biosynthesis and Associated Molecular Innovation: Wen Liu (Chinese Academy of Sciences, P.R. China)
    • Steroid Chemistry: Efficient Synthesis and Biological Studies: Jinghan Gui (Chinese Academy of Sciences, P.R. China)
    • One Health – An Integral Aspect of the Medicines Puzzle for 2040 and Beyond: Geoffrey A. Cordell (U.S.A.)
  4. Role of Chemical and Biological Sciences for Discovery of Modern Drugs II
    • The Infinite Loop: Machine Learning for Discovery, Delivery, and Rapid Manufacturing of Potential Medicines: Bradley L. Pentelute (Massachusetts Institute of Technology, U.S.A.)
    • Antibody-Drug Conjugates (ADCs) – A Perfect Synergy?: John A. Hartley (University College London, U.K.)
    • Developments of Molecular Probes for Detection of Biological Targets: Sun-Joon Min (Hanyang University, Republic of Korea)
    • From Structural Biology to Organic Synthesis: A Collaborative Search for New Anti-Mycobacterial Drugs: Roderick Bates (Nanyang Technological University, Singapore)
  5. Genetic Diseases: From Detection to Therapy
    • Thalassemia: A Model of Genetic Disease: Suthat Fucharoen (Institute of Molecular Biosciences, Mahidol University, Thailand)
    • Over 3 Decades of Organizing Services for Inherited Metabolic Disorders in Thailand: Pornswan Wasant  (Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand)  
    • Gaucher Disease as A Model for Rare Disorders: Ari Zimran (Hebrew University of Jerusalem, Israel)
    • Rare Inborn Metabolic Disorders: From Mystery to Diagnosis and Treatment: Duangrurdee Wattanasirichaigoon (Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand)
    • Newborn Screening by Tandem Mass Spectrometry: From Early Detection of Rare Diseases to Therapy: Nithiwat Vatanavicharn (Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand)
    • Lysosomal Storage Diseases: Progress in Diagnosis and Therapy in Thailand: Thipwimol Tim-Aroon (Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand)
  6. Early Detection and Prevention of Cancer
    • Adductomic Strategies for Emerging Risk Factors in Liver Cancer: John D. Groopman (Johns Hopkins Bloomberg School of Public Health, U.S.A.)
    • Liver Cancer Prevention: Hashem B. El-Serag (Baylor College of Medicine, U.S.A.)
    • Emerging Strategies of Early Detection of Liver Cancer: Xin Wei Wang (National Cancer Institute, U.S.A.)
  7. One Health and Therapeutics
    • Vaccine Manufacturing Considerations for Pandemic Preparedness: Rahul Singhvi (National Resilience, Inc., U.S.A.)
    • Design and Patterns of Optimized Drug Combinations for TB: Bree Aldridge (Tufts University School of Medicine, U.S.A.)
    • Development of Multi-Epitope Subunit Vaccines Against Acinetobacter baumannii: Bernard Arulanandam (Tufts University School of Medicine, U.S.A.)
  8. Antimicrobial Resistance: One Health Perspectives
    • One Health Selection and Transmission of Antibiotic Resistance in Thailand, Argentina and the United Kingdom: Matthew B. Avison (University of Bristol, U.K.)
    • Lessons from Wastewater Surveillance: Impact of COVID-19 on AMR: Motoyuki Sugai (National Institute of Infectious Diseases, Japan)
    • Mining the Epitranscriptome for First-In-Class Antimicrobials: Peter Dedon (Massachusetts Institute of Technology, U.S.A.)
    • AMASS: AutoMated Tool for Antimicrobial Resistance Surveillance System – How Thailand Utilizes Timely Data from 127 Public Hospitals for Actions at the Facility and National Levels: Direk Limmathurotsakul (Faculty of Tropical Medicine, Mahidol University, Thailand)
  9. Zoonotic Diseases
    • Successful One Health Approach to Reduce Zoonotic Disease from Pigs: Cate Dewey (University of Guelph, Canada)
    • Complexity, Context, and Community Engagement: Centering Anthropology Within the One Health Paradigm: Elizabeth Finnis (University of Guelph, Canada)
    • One Health in Actions on Zoonoses and Agrifood Systems: Perspectives for Global Health and Food Security: Thanawat Tiensin (Food and Agriculture Organization of the United Nations (FAO), Italy)
  10. Environmental Risk Factors Affecting Health
    • World Health Organization Calls for Enhanced Multisectoral Action to Improve Chemical Safety and Protect Public Health, Including Through A One Health Approach: Virunya Bhat (WHO, Switzerland)
    • Towards One Health: Toxicokinetics at the Intersection of Human and Ecological Health: Michelle Embry (Health and Environmental Sciences Institute (HESI), U.S.A.)
    • Food Safety from a One Health Perspective: Maged Younes (Robert Gordon University, U.K.)
    • Per- and Polyfluoroalkyl Substances (PFAS): The Complexity in Toxicity and Risk Assessment: Martin van den Berg (Utrecht University, The Netherlands)
    • The Air We Breathe – Chemical Challenges to Health, A UK-Thailand Perspective: Dudley E. Shallcross (University of Bristol, U.K.)
    • PM2.5 Toxicity and Adverse Health Effects: Herman Autrup (University of Aarhus, Denmark)
  11. Protein Changes in Disease
    • How a Single Mutation in CFTR Causes the Systemic Disease Cystic Fibrosis: Interactions, PTMs, and Structure: John Yates III (The Scripps Research Institute, U.S.A.)
    • Ultrasensitive Proteomics for Precision Oncology: Yu-Ju Chen (Institute of Chemistry, Academia Sinica, Chinese Taipei)
    • Navigating Drug-Targetome-Phenotype Interaction and Its Translational Implications: Ho Jeong Kwon (Yonsei University, Republic of Korea)
    • Advancements in Peptidoproteomics for Cancer Research: Sittiruk Roytrakul (National Center for Genetic Engineering and Biotechnology, Thailand)
    • Exploring Microproteins and Interferon Pathways in Colorectal Cancer: Implications for Disease Progression and FOLFOX Chemoresistance: Teck Yew Low (Universiti Kebangsaan Malaysia, Malaysia)
  12. Relationships between Genetic Mutation and the Environment in Cancer and Infectious Diseases
    • Genetic and Epigenetic Cues Shape Initiation, Promotion and Therapy Resistance in Childhood Leukaemia: Tariq Enver (U.K.)
    • Towards an Understanding of Air Pollution Driven Lung Cancer Promotion: Charles Swanton (Francis Crick Institute, U.K.)
    • Axonal Injury Initiates Glioblastoma: Simona Parrinello (University College London, U.K.)
    • What Does Our Knowledge of Innate Immune Regulation During Infection Tell Us About Innate Immune Contribution to Cancer Outcome?: Greg Towers (University College London, U.K.)

CLOSING SESSION:

Roundtable Discussion – Regulatory Innovation

     Moderators: Ram Sasisekharan (U.S.A.)  and Surachoke Tangwiwat (Thailand)

  • U.S. FDA’s Efforts to Advance Gene Therapy Development [Virtual Presentation]: Peter Marks (U.S.A.)
  • Perspectives from the Thai FDA: Worasuda Yoongthong (Thailand)
  • Case Studies of Regulatory Innovations: Ram Sasisekharan (U.S.A.)

Roundtable Discussion – AMR Policy Impacting South and Southeast Asia

      Moderators: Helen Boucher (U.S.A.) and Julie L. Gerberding (U.S.A.)

  • Panelists:
    • Helen Boucher (U.S.A.)
    • George F. Gao (P.R. China)
    • Julie L. Gerberding (U.S.A.)
    • Ramanan Laxminarayan (U.S.A.)
    • David Paterson (Singapore)